You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長江生科(00775.HK)料Pharus檢測獲批時間較藥物短
長江生命科技(00775.HK)聯同長和(00001.HK)投資從事癌症早期檢測分子診斷的研究、開發及商業化業務的Pharus。長江生命科技副總裁及行政總監餘英才表示,癌症檢測市場和商機龐大,屬於高增長行業,長和亦對此有興趣,因此與公司各自對Pharus投資,這項投資將由長江生命科技主導與Pharus共同管理,而長和主要進行財政投資。 餘英才指,Pharus首階段擬在專業實驗室提供專業測試,在得到監管機構認可後,將製造能在廣泛普通實驗室提供的測試。他指,Pharus目前需要集中增加收集臨牀試驗數據,待收集足夠數據,公司就可以向監管機構申請向市場推出產品,由於產品屬於醫學儀器,預料獲得批準的時間比藥物短很多。 對於會否與保險公司合作推出檢測產品,餘英才指,將使用所有途徑增加產品覆蓋,相信Pharus會考慮與任何公司合作,視乎其未來數年工作進度和臨牀試驗結果,若有機會希望可以將其分拆上市。另外,他指,公司使用內部資源投資Pharus,對負債沒有影響,公司亦有評估不同公司前景,希望不久將來有新投資。 副總裁及科學總監杜健明表示,Pharus提供的液體活檢測試採用MicroRNA,測試敏感度較高,同一時間可以多種癌症,與市場上提供的測試不同。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account